Lamprene — Competitive Intelligence Brief

Lamprene (clofazimine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimycobacterial. Area: Metabolic.

marketed Antimycobacterial ATP-binding cassette sub-family G member 2 Metabolic

Target snapshot

Lamprene (clofazimine) — Novartis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lamprene TARGET	clofazimine	Novartis	marketed	Antimycobacterial	ATP-binding cassette sub-family G member 2	1986-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Kaletra	LOPINAVIR	Abbvie Deutschland Gmbh Co. Kg	marketed	Cytochrome P450 3A Inhibitor [EPC]	ATP-binding cassette sub-family G member 2	2000-01-01
Nogitecan	topotecan	Novartis	marketed	topotecan	ATP-binding cassette sub-family G member 2	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimycobacterial class)

1. Epic Pharma Llc · 1 drug in this class
2. Kanchan Hlthcare · 1 drug in this class
3. Novartis · 1 drug in this class
4. Pfizer · 1 drug in this class